Biologics/Immunotherapy News

HONOLULU — Tezepelumab improved outcomes among patients with severe, uncontrolled asthma regardless of BMI, according to an abstract presented at the CHEST Annual Meeting.

HONOLULU — Children with uncontrolled moderate to severe asthma experienced fewer severe exacerbations requiring systemic corticosteroids when treated with dupilumab, according to a poster presented at the CHEST Annual Meeting.

The FDA has granted priority review to a supplemental biologics license application for dupilumab in the treatment of children aged 1 to 11 years with eosinophilic esophagitis, according to a press release.

The Allergy-Immunology Joint Task Force on Practice Parameters has issued guidelines for the medical management of chronic rhinosinusitis with nasal polyps, according to a review published in Annals of Allergy, Asthma & Immunology.

Mepolizumab and benralizumab were associated with prolonged reductions in oral corticosteroid use among real-world patients with severe eosinophilic asthma, according to data in The Journal of Allergy and Clinical Immunology: In Practice.

More children with asthma who were treated with dupilumab than placebo met criteria as responders in percent predicted FEV1 measurements, according to an abstract presented at the European Respiratory Society International Congress.

Patients with severe asthma achieved clinical remission based on a four-component definition with 52 weeks of mepolizumab, according to an abstract presented at the European Respiratory Society International Congress.

Dupilumab may be a safe and effective therapy for patients with drug reactions with eosinophilia and systemic symptoms, or DRESS, according to a case series published in The Journal of Allergy and Clinical Immunology: In Practice.

Treatment with dupilumab reduced Staphylococcus aureus colonization and infection in patients with atopic dermatitis, correlating with improved outcomes, according to a study published in The Journal of Allergy and Clinical Immunology.

Treatment with dexpramipexole decreased eosinophil levels and improved FEV1 among adults with asthma with no serious adverse events, according to a study published in The Journal of Allergy and Clinical Immunology.